Table 2– Long-term (24 month) treatment outcomes after treatment with delamanid in combination with an optimised background treatment regimen: MDR- and XDR-TB patients.
Treatment outcome | Long-term treatment# | Short-term treatment¶ | All patients+ |
Favourable | 143 (74.5; 67.7–80.5)§ | 126 (55.0; 48.3–61.6)§ | 269 (63.9; 59.1–68.5) |
Cured | 110 (57.3; 50.0–64.4) | 111 (48.5; 41.8–55.1) | 221 (52.5; 47.6–57.4) |
Completed | 33 (17.2; 12.1–23.3)§ | 15 (6.6; 3.7–10.6)§ | 48 (11.4; 8.5–14.8) |
Unfavourable | 49 (25.5; 19.5–32.3)§ | 103 (45.0; 38.4–51.7)§ | 152 (36.1; 31.5–40.9) |
Died | 2 (1.0; 0.1–3.7)§ | 19 (8.3; 5.1–12.7)§ | 21 (5.0; 3.1–7.5) |
Failed | 32 (16.7; 11.7–22.7) | 26 (11.4; 7.6–16.2) | 58 (13.8; 10.6–17.4) |
Defaulted | 15 (7.8; 4.4–12.6)§ | 58 (25.3; 19.8–31.5)§ | 73 (17.3; 13.8–21.3) |
Data are presented as n (%; 95% CI). MDR: multidrug-resistant; TB: tuberculosis; XDR: extensively drug-resistant. #: 192 patients received delamanid (100 mg and/or 200 mg twice a day) for at least 6 months; ¶: 229 patients received delamanid (100 mg or 200 mg twice a day) or placebo for 2 months; +: n=421; §: differences between the long-term and the short-term treatment groups for the corresponding treatment outcome were statistically significant (p<0.001), all other differences did not reach statistical significance (p≥0.05).